Q2 Earnings Forecast for VERV Issued By Lifesci Capital

Verve Therapeutics, Inc. (NASDAQ:VERV) – Analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for shares of Verve Therapeutics in a research report issued on Tuesday, June 17th. Lifesci Capital analyst C. Jubinville anticipates that the company will post earnings per share of ($0.71) for the quarter. Lifesci Capital currently has a “Market Perform” rating and a $12.00 target price on the stock. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share. Lifesci Capital also issued estimates for Verve Therapeutics’ Q3 2025 earnings at ($0.71) EPS and Q4 2025 earnings at ($0.70) EPS.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 303.64% and a negative return on equity of 35.81%. The business had revenue of $32.98 million for the quarter, compared to the consensus estimate of $7.13 million.

VERV has been the topic of several other reports. HC Wainwright reaffirmed a “neutral” rating and set a $13.50 price objective on shares of Verve Therapeutics in a research report on Wednesday. Guggenheim lifted their price target on Verve Therapeutics from $18.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, April 15th. Canaccord Genuity Group cut Verve Therapeutics from a “strong-buy” rating to a “hold” rating and reduced their price target for the stock from $39.00 to $13.00 in a research note on Tuesday. Cantor Fitzgerald raised Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, April 15th. Finally, Wall Street Zen raised shares of Verve Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Verve Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $14.75.

Verve Therapeutics Price Performance

Shares of NASDAQ VERV opened at $11.12 on Thursday. Verve Therapeutics has a 1 year low of $2.86 and a 1 year high of $11.41. The stock has a market capitalization of $991.24 million, a P/E ratio of -5.27 and a beta of 1.67. The company’s 50-day moving average is $5.18 and its 200 day moving average is $5.88.

Institutional Investors Weigh In On Verve Therapeutics

A number of institutional investors have recently modified their holdings of VERV. IFP Advisors Inc raised its position in shares of Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after purchasing an additional 8,237 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Verve Therapeutics in the fourth quarter worth about $50,000. KFG Wealth Management LLC bought a new position in shares of Verve Therapeutics in the first quarter worth approximately $46,000. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Verve Therapeutics during the first quarter valued at approximately $47,000. Finally, E Fund Management Co. Ltd. purchased a new position in Verve Therapeutics in the 1st quarter worth approximately $48,000. 97.11% of the stock is owned by hedge funds and other institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.